GlucoTrack, Inc.
GCTK Healthcare Medical Instruments & Supplies
In the quarter to June 2026, EPS grew 92.1%, free cash flow grew 3.42% and total debt rose 777.8%, each against the same quarter a year earlier.
Follow GCTK
GlucoTrack, Inc. (GCTK) EV/Sales
As of 16 October 2026, GlucoTrack, Inc. (GCTK) trades at a EV/Sales of 5.1×. Over the past ten years it has ranged from −38.5× (June 2025) to 913,665,851× (November 2019); the current reading is higher than 21% of that period. That is above the Medical Instruments & Supplies industry median of 2.9× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2019 | 522,885,374× | 5,520.31% |
| FY2018 | 9,303,495× | (62.71%) |
| FY2017 | 24,952,325× | (9.87%) |
| FY2016 | 27,686,110× | (78.32%) |
| FY2015 | 127,723,890× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2019 | 522,885,374× | 7.31% |
| Sep 2019 | 487,288,451× | 127.01% |
| Jun 2019 | 214,658,117× | 172.21% |
| Mar 2019 | 78,858,044× | 185.44% |
| 13 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| RVP Retractable Technologies, Inc. compare | −0.6× |
| RGNT Regentis Biomaterials Ltd. compare | n/m |
| MHUAF Meihua International Medical Technologies Co., Ltd. compare | n/m |
| CUPR Cuprina Holdings (Cayman) Limited compare | n/m |
| LUCY Innovative Eyewear, Inc. compare | 0.4× |
| BNGO Bionano Genomics, Inc. compare | 0.7× |
| FEMY Femasys Inc. compare | 3.4× |
| NXGL NexGel, Inc. compare | 4.3× |
| GCTK GlucoTrack, Inc. | 5.1× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)